A Phase III, Randomized, Double-Masked, Active-Controlled, Parallel-Group, Multi-center Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Glaucoma or Ocular Hypertension - Spectrum 3 Study
Phase of Trial: Phase III
Latest Information Update: 19 Dec 2018
At a glance
- Drugs Omidenepag isopropyl (Primary) ; Timolol
- Indications Glaucoma; Ocular hypertension
- Focus Registrational; Therapeutic Use
- Acronyms Spectrum 3
- Sponsors Santen Inc
- 22 Oct 2018 According to a Santen Inc media release, this trial is included under SPECTRUM program.The SPECTRUM program includes two pivotal, phase III trials, SPECTRUM 3 (NCT03691649) and SPECTRUM 4 (NCT03691662).
- 28 Sep 2018 Status changed from planning to recruiting.
- 28 Sep 2018 New trial record